Predicting Patient Drug Response to Tailor Cancer Treatments
Discover how patient-derived 3D tumor models transform precision oncology—replicating real cancer microenvironments to improve drug testing, accelerate research, and drive better treatment outcomes.
Predicting Patient Drug Response to Tailor Cancer Treatments
Discover how patient-derived 3D tumor models transform precision oncology—replicating real cancer microenvironments to improve drug testing, accelerate research, and drive better treatment outcomes.
Personalized Therapies
Targeted treatments tailored to each patient's unique cancer profile.
No More Guesswork
Reduce side effects and take evidence-based decisions for every cancer case.
Better Results, Faster
We test multiple therapies in parallel, identifying the right treatment faster.
End-to-End Precision Oncology
PreComb collaborates with research partners by providing expert guidance in selecting and generating patient-derived 3D tumor models tailored to their studies. By leveraging our automated screening platform, researchers gain access to standardized, reproducible testing with real-time insights, enabling more predictive and translational cancer research.
- Customize Your Tumor Models – Work with our team to select and generate the most relevant 3D tissue models for your research.
- Automate & Scale Screening – Utilize our high-throughput platform to run standardized drug testing with real-time imaging.
- Gain Actionable Insights – Analyze tumor response dynamics to refine experimental approaches and accelerate discoveries.
OVERVIEW
End-to-End Precision Oncology
PreComb collaborates with research partners by providing expert guidance in selecting and generating patient-derived 3D tumor models tailored to their studies. By leveraging our automated screening platform, researchers gain access to standardized, reproducible testing with real-time insights, enabling more predictive and translational cancer research.
- Customize Your Tumor Models – Work with our team to select and generate the most relevant 3D tissue models for your research.
- Automate & Scale Screening – Utilize our high-throughput platform to run standardized drug testing with real-time imaging.
- Gain Actionable Insights – Analyze tumor response dynamics to refine experimental approaches and accelerate discoveries.
OVERVIEW
End-to-End Precision Oncology
PreComb collaborates with research partners by providing expert guidance in selecting and generating patient-derived 3D tumor models tailored to their studies. By leveraging our automated screening platform, researchers gain access to standardized, reproducible testing with real-time insights, enabling more predictive and translational cancer research.
1. Generate 3D Microtumors
2. Automate & Scale Screening
3. Gain Actionable Insights
Transform Oncology
with 3DTwin®
Discover how patient-derived tumor models enable faster, evidence-based treatment decisions, reduce side effect, and improve outcomes for every cancer case.
Accelerate Drug Discovery with PreComb
PreComb’s 3DTwin® technology revolutionizes pharmaceutical R&D by providing patient derived tumor models that deliver faster, clinically relevant insights. Optimize your drug discovery process, reduce costs, and bring therapies to market with unmatched precision.
- Faster Drug Development: Identify the most effective compounds quickly using real patient tumor models.
- Cost-Effective R&D: Minimize time and resources spent on preclinical trials.
- Clinically Relevant Results: Increase the success rate of clinical trials with human-relevant data.
- Scalable Solutions: Test multiple molecules and therapy combinations simultaneously.
Advancing Cancer Care for Oncologists & Patients
Our groundbreaking 3DTwin® technology is designed to revolutionize cancer diagnostics and treatment. While our solution is still in the research and development phase and not yet certified for clinical application, we are working tirelessly with academic and industry partners to refine and validate our approach, aiming to offer our tests to the public as soon as possible.
For now, our focus remains on providing this innovative platform to researchers, pharmaceutical companies, and academics. (By ensuring that our solution is safe, reliable, and scientifically proven,) we are paving the way for future clinical applications that will deliver unprecedented precision and personalized care for every cancer patient.
Stay connected and be the first to know when our tests become available to patients and oncologists:
- Register here to receive updates on our progress and availability.
- Follow us on Instagram to learn more about the latest advancements in our technology and mission to cancer care.
Meet the Founders
PreComb was founded in 2018 by a team of serial biotech entrepreneurs with deep expertise in cell culture technology, tissue engineering, drug development, lab automation, and data science. With leadership experience at industry giants like Novartis, Alcon, and InSphero, they bring a proven track record of scientific innovation, company building, and commercial execution to transform cancer research and precision medicine.
🔬 50+ years of combined experience in biotech and pharma
🏆 3 biotech companies founded, with 2 major exits
🧬 20 years of expertise in 3D tissue models
📑 50+ scientific publications and 12 patents
Improve Patient Outcomes With 3D Tumor Modeling
Gain exclusive insights into functional precision oncology and 3D microtumors with our latest scientific white paper. Discover cutting-edge research, real-world applications, and key advantages for research facilities, academic institutions, and pharma companies.